Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)- hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A designed, potent, orally active inhibitor of cholesterol absorption

Journal of Medicinal Chemistry

Volumn 41, Issue 6, 1998, Pages 973-980

  Rosenblum, Stuart B ^a   Huynh, Tram ^a   Afonso, Adriano ^a   Davis Jr , Harry R ^a   Yumibe, Nathan ^a   Clader, John W ^a   Burnett, Duane A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 FLUOROPHENYL) [3 (4 FLUOROPHENYL)HYDROXPROPYL](4 HYDROXYPHENYL) 2 AZETIDINONE; 1,4 BIS(4 METHOXYPHENYL) 3 (3 PHENYLPROPYL) 2 AZETIDINONE; CHOLESTEROL; CHOLESTEROL ESTER; HYPOCHOLESTEROLEMIC AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; OXIDATION; STRUCTURE ACTIVITY RELATION; SYRIAN HAMSTER;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CRICETINAE; DRUG DESIGN; LIVER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032510318     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970701f     Document Type: Article

References (25)

1. The Expert Panel. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J. Am. Med. Assoc. 1993, 269, 3015-3023
2. (a) Wirebaugh, S. R.; Shapiro, M. L.; McIntyre, T. H.; Whitney, E. J. A Retrospective Review of the Use of Lipid-Lowering Agents in Combination, Specifically, Gemfibrozil and Lovastatin. Pharmacotherapy 1992, 12, 445-450.
3. (b) Krause, B. R.; Sliskovic, D. R.; Bocan, T. M. A. Emerging Therapies in Atherosclerosis. Exp. Opin. Invest. Drugs 1995, 4, 353-387.
4. Dujovne, C. A.; Harris, W. S.; Gelfand, R. A.; Morehouse, L. A.; McCarthy, P. A.; Chandler, C. E.; DeNinno, M. P.; Harwood, H. J., Jr.; Newton, F. A.; Shear, C. L. Investigations of the Effects of Synthetic Saponons on Cholesterol Absorption and Serum Cholesterol Levels. In Atherosclerosis X; Wbodford, F. P., Davignon, J., Sniderman, A., Eds.; Elseyier Science: New York, 1995; pp 298-306.
5. Bergman, M.; Morales, H.; Mellars, L.; Kosoglou, T.; Burrier, R.; Davis, H. R.; Sybertz, E. J.; Pollare, T. The Clinical Development of a Novel Cholesterol Absorption Inhibitor. Proceedings of the XII International Symposium on Drugs Affecting Lipid Metabolism, Nov. 7-10, 1995, Houston, TX.
6. Marcelino, J. J.; Feingold, K. R. Inadequate Treatment with HMG-CoA Reductase Inhibitors by Health Care Providers. Am. J. Med. 1996, 100, 605-610.
7. Clader, J. W.; Burnett, D. A.; Caplen, M. A.; Domalski, M. S.; Dugar, S.; Vaccaro, W.; Sher, R.; Browne, M. E.; Zhao, H.; Burrier, R. E.; Salisbury, B.; Davis, H. R., Jr.; 2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus. J. Med. Chem. 1996, 39, 3684-3693.
8. (a) Dugar, S.; Kirkup, M. P.; Clader, J. W.; Lin, S. L.; Rizvi, R.; Snow, M. E.; Davis, H. R., Jr.; McCombie, S. W. Gamma-Lactams and Related Compounds as Cholesterol Absorption Inhibitors: Homologs of the Beta-Lactam Cholesterol Absorption Inhibitor SCH 48461. Bioorg. Med. Chem. Lett. 1995, 5, 2947-2952.
9. (b) Dugar, S.; Yumibe, N.; Clader, J. W.; Viziano, M.; Huie, K.; Van Heek, M.; Compton, D. S.; Davis, H. R., Jr. Metabolism and Structure Activity Data Based Drug Design: Discovery of (-) SCH 53079 an Analogue of the Potent Cholesterol Absorption Inhibitor (-) SCH 48461. Bioorg. Med. Chem. Lett, 1996, 6, 1271-1274.
10. (c) McKittrick, B. A.; Ma, K.; Dugar, S.; Clader, J. W.; Davis, H., Jr.; Czarniecki, M.; McPhail, A. T. Stereoselective Synthesis and Biological Activity of cis Azetidinones as Cholesterol Absorption Inhibitors. Bioorg. Med. Chem. Lett. 1996, 6, 1947-1950.
11. Rosenblum, S. B.; Dugar, S.; Burnett, D. A.; Clader, J. W.; McKittrick, B. A. Hydroxy-Substituted Azetidinone Compounds Useful as Hypocholesterolemic Agents. U.S. Patent 5 631 365, 1997; World (PCT) Patent WO9508532-A1, 1995.
12. (a)McCarthy, P. A.; DeNinno, M. P.; Morehouse, L. A.; Chandler, C. E.; Bangerter, F. W.; Wilson, T. C.; Urban, F. J.; Walinsky, S. W.; Cosgrove, P. G.; Duplantier, K.; Etienne, J. B.; Fowler, M. A.; Lambert, J. F.; O'Donnell, J. P.; Pezzullo, S. L.; Watson, H. A., Jr.; Wilkins, R. W.; Zaccaro, L. M.; Zawistoski, M. P. 11-Ketotigogenin Cellobioside (Pamaqueside): A Potent Cholesterol Absorption Inhibitor in the Hamster. J. Med. Chem. 1996, 39, 1935-1937.
13. (b) DeNinno, M. P.; McCarthy, P. A.; Duplantier, K. C.; Eller, C.; Etienne, J. B.; Zawistoski, M. P.; Bangerter, F. W.; Chandler, C. E.; Morehouse, L. A.; Sugerman, E. D.; Wilkins, R. W.; Woody, H. A.; Zaccaro, L. M. Steroidal Glycoside Cholesterol Absorption Inhibitors. J. Med. Chem. 1997, 40, 2547-2554.
14. Burnett, D. A.; Caplen, M. A.; Davis, H. R., Jr.; Burrier, R. E.; Clader, J. W. Azetidinones as Inhibitors of Cholesterol Absorption. J. Med. Chem. 1994, 37, 1733-1736.
15. Salisbury, B. G.; Davis, H. R.; Burrier, R. E.; Burnett, D. A.; Boykow, G.; Caplen, M. A.; Clemmons, A. L.; Compton, D. S.; Hoos, L. M.; McGregor, D. G.; Schnitzer-Polokoff, R.; Smith, A. A.; Weig, B. C.; Zilli, D. L.; Clader, J. W.; Sybertz, E. J. Hypocholesterolemic Activity of a Novel Inhibitor of Cholesterol Absorption, SCH 48461. Atherosclerosis 1995, 115, 45-63.
16. Sybertz, E. J.; Davis, H. R.; Van Heek, M.; Burrier, R. E.; Salisbury, B. G.; Romano, M. T.; Clader, J. W.; Burnett, D. A. SCH 48461, A Novel Inhibitor of Cholesterol Absorption. In Atherosclerosis X; Woodford, F. P., Davignon, J., Sniderman, A., Eds.; Elsevier Science: New York, 1995; pp 311-315.
17. Van Heek, M.; France, C. F.; Compton, D. S.; Mcleod, R. L.; Yumibe, N. P.; Alton, K. B.; Sybertz, E. J.; Davis, H. R., Jr. In Vivo Metabolism-Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH 58235, in the Rat and Rhesus Monkey through the Identification of the Active Metabolites of SCH 48461. J. Pharm. Exp. Ther. 1997, 283, 157.
18. The amino acid hydrolysis product of SCH 48461 is described in ref 6 and had no detectable activity (i.e., LCE reduction) at 50 mg/kg/day in the cholesterol-fed hamster model.
19. Lactone analogues resultingfron from attempted benzylic hydrolysis were tested as a mixture and had no detectable activity at 50 mg/kg/day in the cholesterol-fed hamster model.
20. Park, B. K.; Kitteringham, N. R. Effects of Fluorine Substitution on Drug Metabolism: Pharmacological and lexicological Implications. Drug Metab. Rev. 1994, 26, 605-643.
21. (a) Burnett, D. A. Asymmetric Synthesis and Absolute Stereochemistry of Cholesterol Absorption Inhibitor, SCH 48461. Tetrahedron Lett. 1994, 35, 7339-7342.
22. (b) Braun, M.; Galle, D. A Simple Stereoselective Synthesis of the Cholesterol Absorption Inhibitor (-)-SCH 48461. Synthesis 1996, 819-820.
23. Browne, M.; Burnett, D. A.; Caplen, M. A.; Chen, L. Y.; Clader, J. W.; Domalski, M.; Dugar, S.; Pushpavanam, P.; Sher, R.; Vaccaro, W.; Viziano, M.; Zhao, H. trans-Diastereoselective Synthesis of 3-Alkyl Substituted Beta-Lactams via the Acid Chloride-I mine Reaction of Non-Activated Acid Chlorides. Tetrahedron Lett. 1995, 36, 2555-2558.
24. Negishi, E.; Bagheri, V.; Chatterjee, S.; Luo, F. T.; Miller, J. A.; Stoll, A. T. Palladium-Catalyzed Acylation of Organozincs and Other Organometallics as a Convenient Route to Ketones. Tetrahedron Lett. 1983, 24, 5181-5184.
25. Davis, H. R.; Van Heek, M.; Watkins, R. W.; Rosenblum, S. B.; Compton, D. S.; Hoos, L.; McGregor, D. G.; Pula, K.; Sybertz, E. J. The Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor SCH 58235 Alone and in Combination with HMG-CoA Reductase Inhibitors. Proceedings of the XII International Symposium on Drugs Affecting Lipid Metabolism, Nov. 7-10, 1995, Houston, TX.